USH2A Mutation and Specific Driver Mutation Subtypes Are Associated With Clinical Efficacy of Immune Checkpoint Inhibitors in Lung Cancer

Authors

Dexin Yang
Yuqin Feng
Haohua Lu
Kelie Chen
Jinming Xu
Peiwei Li
Tianru Wang
Dajing Xia
Yihua Wu

Publication Date

2-15-2023

Journal

Journal of Zhejiang University Science B

Abstract

This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog

Keywords

Humans, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Extracellular Matrix Proteins, Immune Checkpoint Inhibitors, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Epidermal growth factor receptor (EGFR) mutation, Immune checkpoint inhibitor (ICI), Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation combined with tumor protein P53 (TP53) mutation, Lung cancer, Usher syndrome type-2A (USH2A) missense mutation

DOI

10.1631/jzus.B2200292

PMID

36751700

PMCID

PMC10260284

PubMedCentral® Posted Date

2-15-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes